Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist
Executive Summary
The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm
You may also be interested in...
Teva Throws Wyeth Year-End Curve Ball With Launch Of Generic Protonix
Teva's launch of a generic version of Wyeth's proton pump inhibitorProtonix (pantoprazole) means that Wyeth must quickly decide how much faith to place in its patent as it negotiates a potential settlement
Teva Throws Wyeth Year-End Curve Ball With Launch Of Generic Protonix
Teva's launch of a generic version of Wyeth's proton pump inhibitorProtonix (pantoprazole) means that Wyeth must quickly decide how much faith to place in its patent as it negotiates a potential settlement
Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model
Following a strategic review of Bristol-Myers Squibb's business, the company's management unveiled a productivity initiative Dec. 5 designed to cut $1.5 billion in costs and fashion the drug maker into a "next-generation biopharma.